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Abstract: This communication article addresses currently available rapid non-invasive methods to
screen and detect periodontitis and dental peri-implantitis. In this regard, oral fluid biomarkers
have been researched extensively but self-reported oral health (SROH)-questionnaires have also been
developed. Both alternatives may offer a quick and easy way to screen and detect diseased patients.
Active matrix metalloproteinase (aMMP-8) is one of the most validated biomarkers for screening and
detecting periodontal breakdown related to periodontitis and peri-implantitis and monitoring their
treatment effects revealing successful, less- and non-successful treatment results. Currently available
aMMP-8 lateral-flow technologies allow this kind of analysis, as demonstrated here, to be conducted
quantitatively online and real-time as point-of-care/chairside testing in dental and even medical
care settings. In this study, an aMMP-8 peri-implant sulcular fluid point-of-care-test diagnosed
peri-implantitis and healthy implants far more accurately than bleeding-on-probing or the other
biomarkers, such as polymorphonuclear (PMN)/neutrophil elastase, myeloperoxidase and MMP-9.
Although, SROH-questionnaires allow screening in similar settings but they lack the information
about the current disease activity of periodontitis and peri-implantitis, which is of essential value
in periodontal diagnostics and treatment monitoring. Thus, both methods can be considered as
adjunct methods for periodontitis and peri-implant diagnostics, but the value of oral fluid biomarkers
analysis does not seem to be substitutable.
Keywords: periodontitis; peri-implantitis; screening; point-of-care testing; biomarkers; aMMP-8;
biosensors; point-of-care diagnostics
1. Introduction
Salivary/oral fluid biomarkers such as active matrix metalloproteinase-8 (aMMP-8) are becoming
increasingly useful in the rapid diagnosis of periodontitis and dental peri-implantitis as documented
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in several studies [1–3]. Proteolytic enzymes capable of degrading connective tissue, as well as
their activators and inhibitors, have been a natural target to identify promising candidates causing
loss of attachment in both periodontitis and peri-implantitis. These include but are not limited to
matrix metalloproteinase-8 (MMP-8, neutrophil collagenase), matrix metalloproteinase-9 (MMP-9,
gelatinase B), polymorphonuclear leukocyte (PMN)/neutrophil elastase, myeloperoxidase (MPO) and
tissue inhibitor of metalloproteinases 1 (TIMP-1). Recently, the world workshop on periodontal
and peri-implant diseases classifications emphasized the utilization of validated biomarkers in the
case definition systems [4,5]. Recently, Sorsa et al. [6] especially implicated the oral mouthrinse
aMMP-8 as the needed biomarker for the latest periodontitis classification system [4]. Such oral fluid
biomarkers are now commercially available as quantitative point-of-care (PoC) kits for periodontitis
and dental peri-implantitis [1–3]. Examples regarding aMMP-8 are the quantitative reader equipped
oral fluid (mouthrinse, gingival crevicular fluid (GCF), and peri-implant sulcular fluid (PISF)) aMMP-8
lateral-flow chairside/PoC tests (PerioSafe and ImplantSafe with ORALyzer kits) [7], which have been
successfully demonstrated in numerous studies globally [6–12]. The MMP-8/aMMP-8 is a promising
candidate biomarker to diagnose, predict, grade periodontitis/peri-implantitis and monitor their
treatments [6–21]. The aMMP-8 test kits have been independently validated in Europe, United States
and Africa [6–12] and also shown to be useful in medical care settings such as in detecting prediabetes
and diabetes at the dental office [22].
Recently, Verhulst et al. [23] demonstrated a self-reported oral health (SROH) questionnaire to
be an easy and quick periodontitis screening method which was commendable and an alternative
screening to biomarkers in oral rinse samples. They also reported total MMP-8, not aMMP-8, as the
only salivary biomarker (out of four biomarkers evaluated) that was not associated with periodontitis.
Although the authors were surprised by this outcome [23], this could have been due to the evaluation
of total MMP-8 instead of aMMP-8 [23,24]. Perhaps, the assessment of the catalytically competent
aMMP-8 instead of total MMP-8 would have shown a direct correlation with periodontal disease
severity and treatment monitoring [6–8,11]. Verhulst et al. [23] also acknowledged that analyzing
aMMP-8 rather than the protein concentration in saliva would have been an alternative choice, as has
been reported by other authors [6–12,24]. The sensitivity and specificity of the SROH questionnaire for
total periodontitis was 85% and 63% while for severe periodontitis, was 65% and 81% [23]. Evidence
from some studies suggests that higher sensitivity (96%) for poor oral hygiene, 95% for chronic
periodontitis and 82.6% for at least two sites with bleeding on probing (BOP) based on aMMP-8 oral
fluid PoC tests can be achieved, hence may be superior to SROH questionnaires [8,23,25].
Currently, there are few peri-implantitis studies comparing aMMP-8 PoC technologies and
biomarkers of peri-implantitis. Thus, one of the aims of this study is to assess the accuracy of aMMP-8
PISF POC test (ImplantSafe) in comparison to several candidate biomarkers of peri-implantitis. Another
aim of this study is to evaluate the value of aMMP-8 lateral-flow PoC technologies in medical and
dental settings for screening and detecting periodontally diseased patients and peri-implantitis patients
in a non-invasive way. In this regard, an example of monitoring the treatment of periodontitis patients
using aMMP-8 mouthrinse POC test (PerioSafe) is presented as well.
2. Materials and Methods
2.1. Patient Selection and Characterization
This clinical study was approved by the local ethical committee of Karolinska Institutet, Sweden
(2016-08-24/2016/1:8 and 24 January 2016.), and the Helsinki University Central Hospital, Finland
(nro260/13/03/00/13, 17 December 2013). The dental implant patient participants (n = 52) were
recruited from the Danakliniken (specialist clinic), Stockholm and Karolinska Institutet, Sweden. The
periodontitis patient participants (n = 15) were recruited from the Capital region and Kirkkonummi
unit for special dental care, Helsinki, Finland. Participants provided a written informed consent in
this study.
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At baseline 26 patients with peri-implantitis and 26 randomly selected controls free from
peri-implantitis and periodontitis were included (Table 1). People above 18 years old were included
in this study. Peri-implantitis was diagnosed as probing pocket depth (PPD) ≥ 4 mm, BOP and
bone loss ≥ 2 mm. Peri-implantitis was graded according to alveolar bone loss and peri-implant
inflammation assessed as the number of pathological pockets (gingival pockets ≥4 mm) and mucosal
inflammation [26]. Controls were selected if they were free from peri-implantitis and periodontitis.
At baseline, the controls were investigated in the same way as the peri-implantitis patients. All
participants in this investigation were asked to respond to a validated questionnaire, comprising of
various questions related to family history, medication, previous diseases in particular inflammatory
disorders, diet, smoking, pulmonary diseases, socioeconomic factors, stress and information about
general oral health status.
A standardized dental examination, including X-rays, was performed and collection of PISF
samples using PoC tests were performed. Participants were examined clinically for number of teeth
and implants present, soft tissue pathologies and periodontal status, including PPD of six sites
per implant/tooth, BOP and plaque score as present or absent, mobility and furcation involvement
(teeth) were recorded. A standard millimeter graded Hu-Friedy probe (Hu-Friedy Manufacturing
Co., LLC, Chicago, IL, USA) was used to record the PPD around the implants. The periodontal
status of all participants was classified according to clinical and radiographic criteria, such as number
of pathological pockets ≥4 mm and gingival inflammation. Digital intra-oral/bitewing/panoramic
radiographs were taken at the regular check-ups of all participants by the dentist.
Fifteen periodontitis patients (8 males and 7 females) aged 34 to 65 years were recruited and their
periodontal status was classified according to clinical and radiographic criteria, such as number of
pathological pockets ≥4 mm, gingival inflammation and alveolar bone loss (see Table 2). One of the
patients had type II diabetes, one had Chron’s disease and epilepsy and one had depression; these
patients had appropriate medication for these diseases. A standard WHO probe was used to record
periodontal status. All the patients received anti-infective treatment/scaling and root planing (SRP)
at baseline and at 4 weeks (1st recall visit). The effect of the periodontal treatment was monitored
using an aMMP-8 mouthrinse PoC test kit (PerioSafe-ORALyzer kit by Medix Biochemica Ltd, Espoo,
Finland) at baseline, 4 weeks (1st recall visit) and 8 weeks (2nd recall visit) according to manufacturer’s
instructions as described earlier [7,8]. Patients received the periodontal treatment after the mouthrinse
samples were collected and analyzed by the aMMP-8 test kit. Seven periodontitis patients decided to
end the periodontal treatment monitoring program after 4 weeks (1st recall visit) for unknown reasons.
Table 1. Demographics of the study population.
Condition/Variable Peri-Implantitis (n = 26) Controls (n = 26) p-Value
Age, mean ± SD 67.31 ± 10.97 59.38 ± 9.39 0.007
Gender, n
Female 14 19 0.249
Male 12 7
Smoking, n
Yes 2 8 0.075
No 24 18
PPD < 4 mm 0 20
<0.001PPD = 4–5 mm 4 5
PPD > 5 mm 22 1
PPD (mm), mean ± SD 7.77 ± 1.92 3.35 ± 0.75 <0.001
Diagnostics 2020, 10, 562 4 of 12
Table 1. Cont.
Condition/Variable Peri-Implantitis (n = 26) Controls (n = 26) p-Value
Plaque, n
Yes 10 0 0.001
No 16 26
BOP, n
Yes 17 6 0.005
No 9 20
Calculus (subgingival), n
Yes 0 2 0.49
No 26 24
Suppuration, n
Yes 15 0 <0.001
No 11 26
CVD, n
Yes 6 3 0.465
No 20 23
Hypertension, n
Yes 4 8 0.324
No 22 18
Diabetes, n
Yes 2 3 1
No 24 23
Osteoporosis, n
Yes 1 0 1
No 25 26
Renal diseases, n
Yes 1 1 1
No 25 25
Rheumatoid arthritis, n
Yes 1 2 1
No 25 24
PPD: probing pocket depth; BOP: bleeding on probing; CVD: cardiovascular disease; for clinical parameters plaque,
BOP, calculus, suppuration yes/no: present/absent on the implant sites. p-value calculated continuous variables by
Mann–Whitney test (exact, 2-sided) and for categorical variables by Fisher’s exact test (2-sided).
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Table 2. Effects of periodontal treatment; anti-infective treatment/scaling and root planing (SRP) in 15 adult patients with periodontitis to the clinical parameters (the
number of PPD ≥4 mm, CAL mean, BOP) examined base level (n = 15), 1st recall visit (4 weeks, n = 15) and 2nd recall visit (8 weeks, n = 8).
Periodontal Parameters
Baseline (n = 15) 1st Visit (n = 15) 2nd Visit (n = 8)
Min Max Mean (SD) Min Max Mean (SD) Min Max Mean (SD) p-Value * p-Value **
The Number of PPD ≥ 4 mm 29 132 73.8 (35.3) 10 114 36.1 (30.6) 10 65 25.3 (18.1) 0.001 0.001
CAL (mm) Mean 3.6 5.6 4.5 (0.6) 2.8 5.2 4.0 (0.6) 4.3 5.9 5.1 (0.6) 0.072 0.004
BOP (%) 13 75 43.9 (18.0) 9 38 19.8 (7.7) 5 44 20.1 (12.0) 0.001 0.001
PPD: probing pocket depth; CAL: clinical attachment loss; BOP: bleeding on probing (full mouth). * Friedman test, asymptotic, 2-sided (baseline, 1st visit and 2nd visit, n = 8); ** Wilcoxon
signed ranks test, asymptotic, 2-sided (base level and 1st visit, n = 15).
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2.2. PISF Sample Collection
PISF sample collection was conducted step by step according to the manufacturer’s (ImplantSafe
aMMP-8 PoC test by Medix Biochemica Ltd., Espoo, Finland) instructions. The sampling site was
prepared by removal of excess saliva with a short, gentle blast of air. A sterile PISF collection strip
was placed apically as deeply as possible into the sulcus at the sampling site using the tweezers. The
strip was left there for 30 s and was then pulled off with a carrier and placed in the buffer vial for
elusion. The vial was gently turned upside down 5 times. After waiting for 5 min to make sure the
PISF collection strip was totally immersed in the fluid, the tube was once again pivoted 5 times by
turning it carefully upside down.
2.3. Peri-Implant Crevicular Fluid Analysis (aMMP-8 PoC Test and Other Biomarkers)
aMMP-8 PoC ImplantSafe kit samples were analyzed by dipstick, which was dipped with the
yellow absorption zone into the elution fluid until the liquid was visible in the readout window.
This took 12–15 s. After that the dipstick was removed from the elution fluid and placed on a level
surface. The sample first appeared as a blue haze in the readout window, after which the control
line “C” and eventually the test line “T” appeared. The results were read after exactly 5 min. For
the evaluation, the test strip was placed on a horizontal surface. Collected PISF samples were also
analyzed for aMMP-8 by immunofluorometric assay (IFMA); human PMN elastase, MPO, TIMP-1 by
enzyme-linked immunosorbent assay (ELISA) and pro- and active MMP-9 by gelatin-zymography as
described previously [6,27].
2.4. Statistical Analysis
Basic clinical characteristics were summarized for study patients with dental peri-implantitis and
their healthy controls. Comparisons between peri-implantitis and control groups were performed
using nonparametric Mann–Whitney U test (the results were equivalent to t-test) and Fisher’s exact
test. Receiver operating characteristic (ROC) analysis and the area under the ROC curve (AUC) were
used for studying the diagnostic ability of the biomarker candidates to discriminate peri-implantitis
from a healthy implant. The Youden index was used defining the best cut-offs from the ROC curves for
each biomarker. Diagnostic sensitivity (Se), specificity (Sp), the percentage of false negatives (FN) and
false positives (FP), test accuracy (Acc) and Matthews correlation coefficient (MCC) were calculated by
using the best cut-off to assess the quality of classification of dental peri-implant health and disease.
The effect of periodontal treatment on the 15 adult patients with periodontitis was compared by
Friedman test in (the three time points) and by Wilcoxon signed ranks test (base level vs. 1st visit). A
two-tailed p-value < 0.05 was set as statistically significant. Statistical analyses were performed using
SPSS Statistics, version 25 (IBM Corp, Armonk, NY, USA).
3. Results
The aMMP-8 PoC kit correctly diagnosed all 26 peri-implantitis and 26 healthy implant
patients (Figure 1, Tables 1 and 3). Thus, the aMMP-8 ImplantSafe-ORALyzer kit detected
peri-implantitis-affected sites more efficiently than aMMP-8 (IFMA), MMP-8/TIMP-1, PMN elastase,
MPO, TIMP-1, actMMP-9 and proMMP-9 and BOP as illustrated by the ROC analysis in Figure 1 and
Table 3. Furthermore, it should be noted that, in addition to aMMP-8 PoC test, there were also several
other biomarkers that were more efficient than BOP (Figure 1, Table 3).
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Figure 1. Receiver operating characteristic (ROC) analysis illustrating the diagnostic ability of the
biomarker candidates to discriminate peri-implantitis from healthy implant (26 peri-implant and 26
healthy dental implant patients). aMMP-8 PoC test, IFMA, ELISA and gelatin-zymography for indicated
biomarkers and bleeding on probing (BOP) were assessed as described previously [7,12,26,27].
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Table 3. Receiver operating characteristic (ROC) analysis and the area under the ROC curve (AUC) illustrating the diagnostic ability of the biomarker candidates to
discriminate peri-implantitis from a healthy implant (26 peri-implant and 26 healthy dental implant patients). The Youden index was used defining the best cut-offs
from the ROC curves of biomarkers. Diagnostic sensitivity (Se), specificity (Sp), the percentage of false negatives (FN) and false positives (FP), test accuracy (Acc), and
Matthews correlation coefficient (MCC) were calculated for the biomarkers using the best cut-off.
Biomarkers AUC (95% Confidence Interval) p-Value Cut-Off (Youden’s Index) Se (%) Sp (%) FN (%) FP (%) Acc (%) MCC
aMMP-8 PoC test 1.000 (1.000–1.000) <0.001 – 100.0 100.0 0.0 0.0 100.0 1.000
aMMP-8 (IFMA) (ng/mL) 0.829 (0.715–0.943) <0.001 29.4 76.9 80.8 22.2 20.0 78.9 0.577
20.0 80.8 61.5 23.8 32.3 71.2 0.431
MMP-8 per TIMP-1 0.787 (0.663–0.911) <0.001 0.27 80.8 65.4 22.7 30.0 73.1 0.468
Act MMP-9 0.518 (0.358–0.677) 0.826 0.16 96.2 19.2 16.5 45.6 57.7 0.241
Pro MMP-9 0.598 (0.437–0.758) 0.227 0.66 92.3 42.3 15.4 38.5 67.3 0.400
PMN elastase (ng/mL) 0.765 (0.630–0.900) 0.001 20.2 73.1 76.9 25.9 24.0 75.0 0.500
MPO (ng/mL) 0.763 (0.632–0.894) 0.001 238.2 65.4 80.8 30.0 22.7 73.1 0.468
BOP (yes/no) 0.712 (0.568–0.855) 0.009 0.50 65.4 76.9 31.0 26.1 71.2 0.426
TIMP-1 (ng/mL) 0.593 (0.434–0.753) 0.249 36.8 73.1 53.8 33.3 38.7 63.5 0.274
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The aMMP-8 PoC systems can also do an on-line and real-time quantitative monitoring of
successful (−), less- and non-successful (+) periodontal treatment effects of anti-infective treatment/SRP
(Figure 2). In Figure 2, SRP reduced most (11/15) of the elevated (+) aMMP-8 levels to (−) below 20
ng/mL (cut-off) while 2/15 of cases reduced but remained elevated (+) at the 1st and 2nd recall visits in
the periodontitis patients [7]. As a whole, the effect of periodontal treatment was significantly positive
on the clinical parameters among the majority of the periodontitis patients (Table 2).
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Figure 2. Effects of periodontal treatment; anti-infective treatment/scaling and root planing (SRP) in 15
adult periodontitis patients with elevated aMMP-8 (+, >20 ng/mL) in their mouthrinses monitored
by aMMP-8 PoC-system (PerioSafe-ORALyzer kit) for 1st recall visit (4 weeks) and 2nd recall visit (8
weeks). (−) indicates <20 ng/mL aMMP-8 in mouthrinse.
4. Discussion
The main finding of this study was that the aMMP-8 PISF PoC test was far more accurate in
diagnosing peri-implantitis and healthy implants than BOP or the other biomarkers of this study.
Furthermore, aMMP-8 levels measured by IFMA had the second-best classification ability, but also
MMP-8 per TIMP-1, PMN elastase and MPO showed better potential to classify peri-implant disease
and health than BOP. On the other hand, act MMP-9, pro MMP-9 and TIMP-showed lower potential
than BOP. Thus, in addition to aMMP-8, MMP-8 per TIMP-1, PMN elastase and MPO, seem to be
possible alternatives for BOP as more accurate indicators of peri-implant tissue destruction and
peri-implantitis. However, more research is still needed in this regard to confirm this.
Diagnosing periodontitis and peri-implantitis is mainly based on clinical and radiographic
examination, which assess the extent and severity of periodontitis and peri-implantitis. However,
their accuracy in monitoring disease activity, progression and treatment effects is still limited, and,
in this regard, biomarkers, such as aMMP-8, could improve the accuracy of oral periodontal and
peri-implant disease diagnostics [2–4]. On the other hand, SROH questionnaires could be beneficial
screening tools for periodontitis and peri-implantitis, as well, especially related to the important risk
factors, such as smoking and diabetes [4,5], but also in settings where oral rinse and PISF tests or
professional dental equipment and expertise are unavailable. However, the scientifically proven value
of using validated, rapid oral rinse and PISF PoC aMMP-8 biomarkers [6–21] to detect online and
monitor quantitatively periodontitis and peri-implantitis and their disease activity, progression and
treatment effects is something that should not be undermined when screening for these diseases in
dental or medical settings. In this study, the aMMP-8 mouthrinse test measuring the collagenolytic
activity indicated successful, less- and non-successful periodontal treatment effects of anti-infective
Diagnostics 2020, 10, 562 10 of 12
treatment/SRP in patients with periodontitis (Figure 2). We additionally wish to note that the ease-of-use
of the technology matters as well. For example, the method described by Verhulst et al. [23] for the oral
fluid collection coupled with the laborious procedures, including the time-requiring overnight protocol,
for the biomarkers utilized may not be so rapid compared to a quantitative aMMP-8 PoC system such
as PerioSafe/ImplantSafe oral fluid tests which have only 5–6 min chairside turn around (Figures 1
and 2, Table 3) [6,7,12]. Furthermore, in this study, aMMP-8 PISF PoC test had significantly better
discrimination of peri-implantitis disease than MMP-9 and other biomarkers that, to our knowledge,
do not currently have rapid point-of-care/chairside technologies available.
Although this study was conducted in dental care settings, the application of validated aMMP-8
PoC/chairside tests [6–12] could be of scientific value in point-of-care diagnostics of periodontitis and
peri-implantitis in medical care settings as well. There is evidence of a link between severe periodontitis
and several systemic diseases, such as diabetes and cardiovascular diseases [28–30]. For example, the
inflamed periodontal tissues release pro-inflammatory cytokines and tissue destruction mediators into
the circulation system increasing the systemic inflammatory burden [31]. Furthermore, periodontitis
has a two-way relationship with diabetes [29]. Poor periodontal condition may increase, for example,
the risk of insulin resistance and diabetes complications [29]. In this regard, a recent study demonstrated
that oral rinse aMMP-8 PoC/chairside test can also be used for detecting and screening prediabetes and
diabetes in addition to periodontitis in the dental office [22]. As such, aMMP-8 PoC/chairside tests could
also be useful for medical professionals for assessing the risk of ongoing active periodontal breakdown
and its possible systemic effects among their (diabetes) patients. These risk patients could be referred
to a dentist for a periodontal examination and evaluation of their treatment need [28,29]. Finally,
recent studies indicate that diabetes is a risk factor for severe COVID-19 infections [32]. Regarding the
association between periodontitis and diabetes, biomarkers, such as aMMP-8, have been suggested to
be utilized in the identification of patients with diabetes and active periodontal disease for referring
them to targeted prevention for COVID-19 [33,34]. In conclusion, the relationship between periodontitis
and several systemic diseases offers many possibilities for future studies regarding aMMP-8 oral fluid
testing and other biomarkers linking dental and medical professionals.
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